| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $313.7M | — | +4.8% |
| Cost of Revenue | $161.8M | — | +4.7% |
| R&D Expense | $43.0M | — | +5.1% |
| SG&A Expense | $67.7M | — | +8.8% |
| Operating Income | $35.1M | — | +19.4% |
| Pre-tax Income | $32.3M | — | +50.1% |
| Income Tax | $8.4M | — | +56.1% |
| Net Income | $23.9M | — | +48.1% |
| EPS (Basic) | $0.86 | — | +48.3% |
| EPS (Diluted) | $0.83 | — | +45.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $147.3M | -18.2% | +8.3% |
| Accounts Receivable | $291.9M | -2.6% | +10.1% |
| Current Assets | $890.5M | -5.0% | +10.1% |
| Total Assets | $1.48B | -4.1% | +4.4% |
| Current Liabilities | $583.0M | -10.4% | +11.9% |
| Long-term Debt | $540.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.2M | — | -110.1% |
| Capital Expenditures | $1.7M | — | -60.4% |
| Investing Cash Flow | -$1.7M | — | +59.0% |
| Financing Cash Flow | -$46.1M | — | +55.9% |
| Free Cash Flow | -$2.9M | — | -141.1% |
| +0.5% |
| Total Liabilities | $1.19B | -5.8% | +4.5% |
| Stockholders' Equity | $293.9M | +3.6% | +3.8% |